DOI: 10.36347/sjmcr.2018.v06i08.019

Pages: 560-562

Imitanib or Glivec® is a thyrosine kinase receptor inhibitor that has revolutionized the prognosis of chronic myeloid leukemia and gastrointestinal stromal tumors. This molecule is not devoid of cutaneous adverse effects. We report two cases of Imatinib-induced psoriasis, successfully managed by topical steroids. The aim of this work was to highlight the main features of Imatinib induced Psoriasis, through a systematic review of cases published in the medical literature, to enable rapid diagnosis and appropriate management of this adverse effect.